Malignant News and Research

RSS

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

A study published in the December issue of The Journal of Nuclear Medicine identified positron emission tomography/computed tomography (PET/CT) scans as a potentially useful tool for predicting local recurrence in lung cancer patients treated with radiofrequency ablation (RFA). RFA, which uses localized thermal energy to kill cancer cells, is increasingly used as an alternative treatment for patients unable to undergo surgery or other therapies to treat lung cancer.

7 Dec 2010

No overall cancer risk in people who donate stem cells

American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

7 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Pharmacyclics, Inc. today announced data from three Chronic Lymphocytic Leukemia presentations at the American Society of Hematology Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports clinical data from a pooled analysis of 54 patients with CLL or Small Lymphocytic Lymphoma treated with PCI-32765.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

New drug for non-Hodgkin’s lymphoma shows promise

Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin’s lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.

5 Dec 2010

URMC's Cone Beam CT scanner studies presented at RSNA 2010

While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.

4 Dec 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

The Myelodysplastic Syndromes Foundation today said significant advances are being made in understanding and treating MDS and a related condition, AML (acute myeloid leukemia). Key studies being presented this week include data on new markers and genetic mutations to predict susceptibility to MDS and response to treatment.

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

4 Dec 2010

SAGE launches two new journals in Drug Safety, Hematology

SAGE Expands Therapeutic Advances series by launching two new journals in Drug Safety and Hematology. SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.

3 Dec 2010

New clue in leukemia mystery

There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.

2 Dec 2010

Mount Sinai’s instructor receives Liz Tilberis Grant from OCRF

AnaLisa DiFeo, PhD, Instructor in the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, has been honored by the Ovarian Cancer Research Fund (OCRF) with the Liz Tilberis Grant.

2 Dec 2010

New radiation-free device to detect breast cancer

A new device may enable breast cancer screening and cancer detection in populations where mammography is not widely available or successful, including women in developing countries, and those under the age of 40.

2 Dec 2010

Wake Forest University to begin clinical trial for low-grade gliomas

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

2 Dec 2010

CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial

More than 9,000 people from more than 90 countries will gather Dec. 8-12, 2010, at the Henry B. Gonzales Convention Center in San Antonio, Texas, for the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

2 Dec 2010

Toshiba introduces women's imaging configuration for Aplio XG at RSNA 2010

Many healthcare providers use ultrasound as a first-line diagnostic tool in detecting and monitoring women's health conditions. To help meet the needs of healthcare providers administering women's imaging, Toshiba has introduced a women's imaging configuration for the Aplio™ XG at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 28 - Dec. 3, 2010.

1 Dec 2010

Experts suggest measure to raise awareness about skin cancer among retired population

Failure to get moles and skin changes checked out by a doctor has contributed to a steep rise in deaths from malignant melanoma among pensioners, experts warned today (Tuesday).

1 Dec 2010

Malignant News and Research

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

PET/CT scan predicts, detects local recurrence after radiofrequency ablation

No overall cancer risk in people who donate stem cells

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New drug for non-Hodgkin’s lymphoma shows promise

URMC's Cone Beam CT scanner studies presented at RSNA 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Research findings could provide breakthrough for development of effective therapies for NSCLC

SAGE launches two new journals in Drug Safety, Hematology

New clue in leukemia mystery

Mount Sinai’s instructor receives Liz Tilberis Grant from OCRF

New radiation-free device to detect breast cancer

Wake Forest University to begin clinical trial for low-grade gliomas

CTRC-AACR Symposium to discuss new findings from breast cancer clinical trial

Toshiba introduces women's imaging configuration for Aplio XG at RSNA 2010

Experts suggest measure to raise awareness about skin cancer among retired population

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News